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Edited by Giulio Superti-FurgaAbstract LPS is the primary ligand of Toll-like receptor 4,
activating it through binding to its accessory protein MD-2.
Murine but not human cells expressing MD-2/TLR4 are also
activated by paclitaxel. Paclitaxel binds to human MD-2. The
binding site of paclitaxel overlaps with the binding site of bis-
ANS and LPS, which results in the ability of taxanes to inhibit
LPS signaling in the system with human receptors. Circular di-
chroic spectra of human MD-2 indicated diﬀerences in the chem-
ical environment in the presence of paclitaxel and docetaxel.
Molecular docking identiﬁed the interacting residues of MD-2
and suggests that hydrophobic interactions govern the binding,
while the C-3 0N group where the paclitaxel and docetaxel diﬀer
is exposed on the surface of MD-2.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Toll-like receptor 41. Introduction
Toll-like receptors (TLRs) sample the environment for com-
pounds with molecular characteristics of pathogenic microor-
ganisms and initiate the innate immune response,
contributing to the development of adaptive immunity [1]. In
addition to molecules speciﬁc for pathogens, TLRs are acti-
vated by endogenous host molecules as well as by some drugs
[2]. One of the most extensively investigated receptors is Toll-
like receptor 4 (TLR4), which is responsible for the activation
by LPS. The lipid A moiety of LPS is recognized by MD-2 [3],
which to a large extent determines the speciﬁcity for diﬀerent
LPS chemotypes [4]. Paclitaxel is a compound originally iso-
lated from the bark of Taxus brevifolia and used in cancer che-
motherapy as a mitotic inhibitor. It binds to the b-subunit of
tubulin and stabilizes polymerized microtubules [5]. Paclitaxel
binds to murine MD-2 and acts as a lipid A mimetic, activating
proinﬂammatory genes and is inhibited by LPS antagonists
[5–7]. Human macrophages or cells expressing human MD-2/
TLR4 do not cause activation of NF-jB [8]. This diﬀerence
parallels the diﬀerences between mouse and human in response*Corresponding author. Address: Department of Biotechnology,
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doi:10.1016/j.febslet.2008.10.037to tetraacylated lipid A, which only activates murine MD-2/
TLR4 while it inhibits LPS signaling through human MD-2
[9]. Activation of paclitaxel is quite speciﬁc as its analogue
docetaxel (Fig. 1) does not have immunostimulatory activity
[5,10]. The absence of immunostimulatory activity of paclitaxel
in the human system might be either due to the lack of binding
to human MD-2 or due to the absence of activation of TLR4
despite binding to MD-2. In the latter case, we anticipated to
observe inhibition of the response to LPS.2. Materials and methods
2.1. Preparation of recombinant human MD-2
Human MD-2 was produced in Escherichia coli as described previ-
ously [11], analyzed by SDS–PAGE and its biological activity tested
on HEK293 cells.2.2. Antibody-sandwich ELISA for the detection of binding of taxanes to
MD-2
A microtiter plate was coated overnight at 4 C with 100 lL/well of
5 lg/mL chicken polyclonal anti-hMD-2 antibodies, diluted in 50 mM
Na2CO3 buﬀer, pH 9.6 and blocked with 1% BSA in PBS. After wash-
ing, 1 lM MD-2 with tested compounds was added and incubated for
2 hours. 0.1 lg/mL of mouse anti-hMD-2 MAb (9B4) and 0.1 lg/mL
of goat anti-mouse IgG conjugated with HRP in PBS were added fol-
lowed by detection at 420 nm after the addition of 100 lL of ABTS
(Sigma). Chicken anti-human MD-2 polyclonal antibodies were pre-
pared against recombinant human MD-2 by GenTel (Madison, WI,
USA), monoclonal mouse anti-human MD-2 9B4 antibodies were
from eBioscience (San Diego, CA, USA), and secondary goat anti-
mouse IgG conjugated with horseradish peroxidase were from Santa
Cruz Biotechnology (Santa Cruz, CA, USA).2.3. Spectroscopic measurements
Fluorescence measurements were performed on a LS55 spectroﬂuo-
rimeter (Perkin–Elmer, UK). All measurements were done at 20 C in
a 5 · 5 mm quartz cell (Hellma, Germany). Excitation was at 385 nm
and emission spectra from 400 to 600 nm were recorded. For displace-
ment assay we used 500 nM bis-ANS and 500 nM MD-2 with added
taxanes. The apparent dissociation constant (Kapp) was obtained by
non-linear ﬁt. Kapp was determined using the equation Kd(tax-
ane) = Kapp/(1 + [bis-ANS]/Kd(bis-ANS)). CD measurements were
performed on a Chirascan CD spectrometer (Applied Photophysics,
UK) at 20 C. Each spectrum was averaged ﬁve times with a band-
width of 1.0 nm and 1.0 s sampling. The concentration of MD-2 was
10 lM for far-UV measurements and ligands were added to 10 lM.
In the near-UV, 10 lM of taxanes and 5 lM of LPS were added to
50 lM MD-2.
2.4. Cell culture, reagents and plasmids
Human embryonic kidney (HEK) 293 cells were used to assay the
inhibition of LPS activation. S-LPS (from Salmonella abortus equi
HL83) was kindly provided by Dr. Brandenburg (Research Centerblished by Elsevier B.V. All rights reserved.
Fig. 1. Chemical structure of paclitaxel (left) and docetaxel (right).
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Institute (Osaka, Japan). Paclitaxel and docetaxel were from
Sigma–Aldrich and Fluka. pDeNy–hMyD88, pDeNy–hTRAF6, pDe-
Ny–hIRAK, pUNO–mTLR4-HA, pUNO–hTLR5 were from Invivo-
Gene. pFlag–CMV–hTLR4, pEFBOS–mMD-2 and pEFBOS–hMD-
2 were used for the expression of TLR4 and MD-2. HEK293 cell dual
luciferase assay was performed as described previously [12].
2.5. Molecular docking
The coordinates of human MD-2 (2E59) and models of paclitaxel
and docetaxel (1JFF) were used for docking calculations with Auto-
Dock [13]. The protein was kept rigid while in paclitaxel and docetaxel
14 rotatable bonds were deﬁned as ﬂexible using the deftors module of
AutoDock. AutoGrid calculation was run with 90 points (separated by
0.375 A˚) in each dimension, using the center of the lipid IVa binding
groove of MD-2 as center. The AutoDock calculation was run using
the Lamarckian Genetic Algorithm with a tstep of 0.2 A˚, qstep of
5.0 and a torsion step (tstep) of 5.0, producing 100 structures.Fig. 2. Paclitaxel and docetaxel bind to the LPS receptor human MD-2. Bind
MD-2 monoclonal antibody as described in methods. Results are mean ± S
experiments.3. Results
3.1. Paclitaxel binds to human MD-2 and overlaps with the
binding site for LPS
Binding studies were performed with recombinant human
MD-2 (Fig. 2). We determined direct binding of taxanes to
MD-2 using a monoclonal antibody that binds to free MD-2
but not to MD-2 with bound LPS [14]. This assay detected de-
creased binding to MD-2 in the presence of paclitaxel and
docetaxel but not with roxithromycin as a control (Fig. 2).
We have previously shown that bis-ANS bound to MD-2 is
displaced by LPS [15]. Paclitaxel caused a concentration-
dependent decrease of bis-ANS ﬂuorescence, indicating com-
petitive binding of paclitaxel to MD-2 (Fig. 3), which was
weaker in comparison to LPS. We calculated a binding con-ing was determined by the ELISA test in competition with anti-human
.E.M. from three parallels representative of at least three independent
Fig. 3. Determination of the binding aﬃnity of taxanes for human
MD-2 based on competition with bis-ANS. The curve indicates the
best ﬁt. The apparent dissociation constant for paclitaxel (n) binding to
MD-2 was 540 ± 56 nM, corresponding to Kd of 27 nM, the apparent
dissociation constant for docetaxel (m) binding to MD-2 was slightly
higher (720 nM, Kd 34 nM). Inset: The apparent dissociation constant
for LPS is 5 nM. Results are representative of at least four independent
experiments.
Fig. 4. Binding of taxanes to human MD-2 causes change in the
chemical environment but no large secondary structure rearrangement.
(A) Near-UV CD spectra of 50 lM MD-2 were recorded in the
absence and with 10 lM paclitaxel, docetaxel or LPS. (B) Far-UV CD
spectra were determined for a 10 lM solution of MD-2 in the presence
of paclitaxel, docetaxel and LPS at 10 lM.
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binds to MD-2 at a slightly lower aﬃnity.
3.2. Change of the chemical environment by binding of taxanes
to MD-2
GM2-ganglioside activating protein, another member of the
ML-superfamily can accommodate diﬀerent lipid molecules
with concomitant adaptation of the binding pocket [16]. In
Der p 2 the bound ligand expands the pocket between the
two beta sheets [17–19]. The presence of three myristate chains
or tetraacylated lipid A does not substantially aﬀect the crystal
structure of MD-2 [20,21]. We used CD spectrometry to detect
the eﬀect of taxanes on the structure of MD-2 (Fig. 4). The far-
UV CD signal of MD-2 decreased less than 10% by the addi-
tion of paclitaxel, docetaxel or LPS, suggesting a small change
of the secondary structure; the expansion of the binding pocket
would probably not disrupt a large fraction of the secondary
structure anyway. Larger spectral changes were observed in
the near-UV region. Changes in the near-UV CD spectra do
not necessarily indicate conformational change of the protein;
it however suggests a diﬀerence in the asymmetric environment
of tyrosine residues of MD-2 upon diﬀerent bound ligands.
Part of this diﬀerence can also be due to the induced CD signal
of the aromatic groups of taxanes.
3.3. Taxanes inhibit activation of human cells induced by LPS
HEK293 cells transfected with the murine but not human
MD-2/TLR4 pair are activated by paclitaxel [8]. The fact that
paclitaxel binds to human MD-2 and competes with LPS
should result in the inhibition of LPS signaling. We determined
that paclitaxel did not activate the NF-jB-reporter in the hu-
man system but showed inhibition of LPS signaling (Fig. 5).
Paclitaxel showed higher inhibition in accordance with its
higher aﬃnity for MD-2. Inhibition of TLR activation by tax-
anes is speciﬁc for MD-2/TLR4, since paclitaxel did not inhibit
activation of TLR5 by ﬂagellin, which also signals through the
MyD88 pathway (Fig. 5c). In order to further exclude the pos-
sibility that mitotic cell-arrest is responsible for the inhibitionof LPS signaling, we performed the same experiment with
nocodazole, which mimicks the eﬀect of taxanes. No inhibition
was observed up to the highest concentration of nocodazole
which caused the same increase of mitotic index as paclitaxel
(Fig. 5d and e).
3.4. Docking of taxanes to human MD-2
Based on the evidence of direct binding of taxanes to MD-2
and their competition with LPS and bis-ANS, we docked the
ligand to the crystal structure of human MD-2 (Fig. 6). Tax-
anes could ﬁt into the binding pocket. Paclitaxel and docetaxel
diﬀer at position C-10 where docetaxel has a hydroxyl group
instead of the acetate and at the C-3 0N position with benz-
amido group of paclitaxel and t-BOC in docetaxel (Fig. 1).
The docking simulations of the two taxanes to human MD-2
resulted in several possible solutions; energetically the most
favorable cluster of both paclitaxel and docetaxel was oriented
with 2-benzoyl group oriented towards the center of the pocket
and displayed numerous contacts with residues Ile61, Phe76,
Leu78, Phe119 and Phe151. The groups at the C-3 0N position
of docetaxel and paclitaxel are located at the entrance of the
binding pocket. Small diﬀerences in the aﬃnity are therefore
probably due to the diﬀerences at position C-10.
Fig. 5. LPS-induced signaling of HEK293/hMD2/hTLR4 cells is inhibited by taxanes. Paclitaxel (A) and docetaxel (B) inhibit LPS signaling through
the human MD-2/TLR4 complex. (C) Paclitaxel does not inhibit cellular activation of TLR5 and (D) nocodazole does not inhibit LPS signaling
despite comparable increase of mitotic index as paclitaxel (E). Mitotic index was determined by ﬂow cytometry. The results shown are mean ± S.E.M.
RLA from three parallels and represent at least three independent experiments.
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The striking structural diﬀerence between paclitaxel and li-
pid A is puzzling as they both bind to the same receptor and
activate the same signaling pathway. The crystal structure of
human MD-2 has been determined with antagonistic lipid
IVa and eritoran while the structure of murine MD-2 has been
determined only bound to the primary interaction site of the
TLR4 ectodomain [20,21]. It is unknown whether the second-
ary binding site of the TLR4 ectodomain interacts with both
the agonist and MD-2 or just with MD-2, which experienced
a major conformational rearrangement upon ligand binding.
The size of the ligand binding pocket is larger in murine than
in human MD-2, which contains more cationic residues at the
edge of the pocket [11,22]. Formation of the complex between
MD-2 and taxanes buries approximately 900 A˚2 of surface
area. Hydrophobic interactions therefore probably play a
dominant role in the interaction. In the favored docking con-formation many hydrophobic side chain residues of the MD-
2 pocket are in close proximity to taxanes (Ile52, Leu61,
Phe76, Leu78, Ile80, Ile94, Tyr102, Phe104, Ile117, Phe119,
Phe121, Ile124, Val135, Phe151, Ile153) (Fig. 6). Replacement
of each of the listed residues in murine MD-2 resulted in a sig-
niﬁcant decrease of activation by paclitaxel. At some positions
(e.g. Phe151 and Ile124) activation by paclitaxel decreased 10-
fold more than decrease of LPS activation [23]. SAR analysis
of the activation of murine macrophages by diﬀerent taxanes
indicates the importance of substituents at the C-3 0N position
[24]. This benzamido group of paclitaxel may, in combination
with the more hydrophobic surface of murine MD-2, form an
interacting area for binding to the ectodomain of TLR4, caus-
ing its dimerization, while neither murine MD-2/docetaxel nor
the more polar human MD-2/paclitaxel complex can contrib-
ute suﬃcient hydrophobic interacting surface area.
CD spectra conﬁrm the interaction of aromatic residues of
MD-2 with taxanes, while we cannot corroborate any large
Fig. 6. Docking of paclitaxel and docetaxel to human MD-2. Docking arrangement, representing the most stable calculated complex of MD-2 with
paclitaxel (blue) and docetaxel (green) is shown in stereo representation. Side chains of interacting residues of MD-2 are shown in cyan and Ca trace
of MD-2 in yellow.
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of paclitaxel to human MD-2 was reported with a docking
study [25]. Both studies strongly support the model of taxol
binding to the binding pocket. While Zimmer et al. propose
an important role for electrostatic interactions, we suggest that
hydrophobic interactions represent the main energetic contri-
bution.
TLR4/MD-2 is activated by endogenous agonists under dif-
ferent pathophysiological processes such as ischemia-reperfu-
sion and other chronic inﬂammatory processes. TLR4
activation is essential for the eﬀective response to chemother-
apy, which requires the activation of the immune response to
tumor cells [26] and therapeutic taxanes might aﬀect those pro-
cesses. As the extensive work on paclitaxel derivatives showed
[5,24] it is possible to dissociate the TLR4/MD-2 from the che-
motherapeutic activity of taxanes. Therefore these types of
compounds could be used as a lead to therapeutic inhibitors
of processes that engage MD-2, such as sepsis or other inﬂam-
matory diseases.
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